GSK - GlaxoSmithKline plc

NYSE - Nasdaq Real Time Price. Currency in USD
42.53
+0.06 (+0.14%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close42.47
Open42.52
Bid42.50 x 1300
Ask42.75 x 1400
Day's Range42.37 - 42.64
52 Week Range36.41 - 43.22
Volume1,428,142
Avg. Volume2,258,807
Market Cap104.76B
Beta (3Y Monthly)0.52
PE Ratio (TTM)42.87
EPS (TTM)0.99
Earnings DateFeb 1, 2017 - Feb 6, 2017
Forward Dividend & Yield1.86 (4.41%)
Ex-Dividend Date2019-08-08
1y Target Est46.25
Trade prices are not sourced from all markets
  • AstraZeneca's Breast Cancer Candidate BLA Gets Priority Review
    Zacks

    AstraZeneca's Breast Cancer Candidate BLA Gets Priority Review

    AstraZeneca (AZN) announces acceptance of BLA seeking approval for trastuzumab deruxtecan in metastatic breast cancer by the FDA. The FDA also grants priority review.

  • Novartis' Jakavi Meets Primary Goal in Phase III for GVHD
    Zacks

    Novartis' Jakavi Meets Primary Goal in Phase III for GVHD

    Novartis' (NVS) phase III REACH2 study on Jakavi for treating patients with steroid-refractory acute graft-versus-host disease meets the primary endpoint of superior overall response rate.

  • Reuters

    Teva's UK arm recalls some batches of Ranitidine - Medicines watchdog

    Teva Pharmaceutical's UK unit has recalled some batches of heartburn medicine Ranitidine, Britain's medicines watchdog said on Thursday, making it the latest drugmaker to pull the product. Teva, the world's largest generic drugmaker, is recalling all unexpired stock of Ranitidine Effervescent Tablets in 150 micrograms and 300 micrograms dosages, the Medicines and Healthcare products Regulatory Agency (MHRA) said https://www.gov.uk/government/news/ranitidine-mhra-drug-alert-issued-for-teva-uk-recall. Teva did not immediately respond to a request for comment.

  • Here’s just how big the performance gap is for British companies exposed to Brexit
    MarketWatch

    Here’s just how big the performance gap is for British companies exposed to Brexit

    The performance of British firms who rely on the majority of their sales from European markets have plunged since the country voted to leave the EU in 2016, according to new data.

  • Should Value Investors Buy GlaxoSmithKline (GSK) Stock?
    Zacks

    Should Value Investors Buy GlaxoSmithKline (GSK) Stock?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • MarketWatch

    Pound surges on report of possible draft Brexit deal

    The British pound jumped Tuesday, shaking off losses seen at the start of the week, after upbeat comments over a possible Brexit deal from the European Union’s negotiator.

  • Is GlaxoSmithKline plc (GSK) Outperforming Other Medical Stocks This Year?
    Zacks

    Is GlaxoSmithKline plc (GSK) Outperforming Other Medical Stocks This Year?

    Is (GSK) Outperforming Other Medical Stocks This Year?

  • GuruFocus.com

    Ariel's Rhupal Bhansali's Philosophy of Non-Consensus Investing

    A summary of Bhansali's investment philosophy and four stock picks Continue reading...

  • The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo
    Zacks

    The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo

    The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo

  • Emergent's Chikungunya Vaccine Candidate Gets EMA's PRIME Tag
    Zacks

    Emergent's Chikungunya Vaccine Candidate Gets EMA's PRIME Tag

    Emergent's (EBS) chikungunya vaccine candidate CHIKV VLP gains the PRIME status from the Committee for Medicinal Products for Human Use in Europe.

  • Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals
    Zacks

    Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals

    FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.

  • Hedge Funds Sold GlaxoSmithKline plc (GSK) A Little Bit Too Early
    Insider Monkey

    Hedge Funds Sold GlaxoSmithKline plc (GSK) A Little Bit Too Early

    Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of the third quarter of 2018 as investors first worried over the possible ramifications of rising interest rates and the escalation of the trade war with China. The hedge funds and institutional investors we track […]

  • Hedge Funds Have Never Been More Bullish On Danaher Corporation (DHR)
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Danaher Corporation (DHR)

    Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The last 12 months is one of those periods, as the Russell 2000 […]

  • Reuters

    UPDATE 3-GSK recalls popular heartburn drug Zantac globally after cancer scare

    GlaxoSmithKline on Tuesday said it is recalling the popular heartburn medicine Zantac in all markets as a "precaution", days after the U.S. Food and Drug Administration found "unacceptable" levels of probable cancer-causing impurity in the drug. Zantac, also sold generically as ranitidine, is the latest drug in which cancer-causing impurities have been found. Britain's medicines watchdog said GlaxoSmithKline (GSK) was recalling four prescription-only Zantac medicines: a syrup, an injection and tablets of 150 and 300 milligram (mg) dosages.

  • Emergent's Vaccine Profile Boosts Sales Despite Stiff Rivalry
    Zacks

    Emergent's Vaccine Profile Boosts Sales Despite Stiff Rivalry

    Emergent's (EBS) vaccine portfolio holds great potential with the newly-acquired Narcan nasal spray progressing well. Severe rivalry remains a concern though.

  • Bloomberg

    Trio Wins Nobel for Oxygen Studies That Led to Anemia Drugs

    (Bloomberg) -- Three researchers from the U.S. and Britain won a Nobel Prize for showing how cells sense and adapt to changing oxygen levels, a line of research that’s already led to the development of new drugs.Americans William Kaelin of the Dana-Farber Cancer Institute in Boston and Gregg Semenza of Baltimore’s Johns Hopkins Medicine, and Peter Ratcliffe of the Francis Crick Institute in London received this year’s award for physiology or medicine, the Nobel Assembly at the Karolinska Institute said Monday in a statement.“The seminal discoveries by this year’s Nobel laureates revealed the mechanism for one of life’s most essential adaptive processes,” the assembly said in the statement. “Their discoveries have also paved the way for promising new strategies to fight anemia, cancer and many other diseases.”Semenza and Ratcliffe separately studied the processes surrounding the sensing of oxygen, and found it was at work in virtually all the body’s tissues. Semenza worked in the 1990s on identifying a protein complex that binds to cells’ DNA in response to levels of oxygen in the environment.The complex, called hypoxia inducible factor, regulates production of red blood cells. The science behind it is the basis for an anemia drug codeveloped by AstraZeneca Plc and Fibrogen Inc. called roxadustat that was approved in China in December.Astra is just a few steps away from bringing the drug to patients, said Mene Pangalos, executive vice president of biopharmaceutical research and development, in an email. “This would never have been possible without early breakthroughs of this year’s Nobel winners,” he said.GlaxoSmithKline Plc has filed for Japanese approval of a drug based on the mechanism, called daprodustat. Kaelin’s work linked the same oxygen-regulating machinery to a role in cancer, which is also being mined for potential therapeutics.Annual prizes for achievements in physics, chemistry, medicine, peace and literature were established in the will of Alfred Nobel, the Swedish inventor of dynamite, who died in 1896. The total amount for each of the 2019 prizes is 9 million kronor ($909,000).(Updates with company comment in sixth paragraph)\--With assistance from John Lauerman.To contact the reporters on this story: Niklas Magnusson in Stockholm at nmagnusson1@bloomberg.net;Veronica Ek in Stockholm at vek@bloomberg.netTo contact the editors responsible for this story: Jonas Bergman at jbergman@bloomberg.net, ;Tasneem Hanfi Brögger at tbrogger@bloomberg.net, Eric PfannerFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Theravance Pipeline Strong, Dependence on Yupelri a Concern
    Zacks

    Theravance Pipeline Strong, Dependence on Yupelri a Concern

    Theravance's (TBPH) newly-launched COPD drug Yupelri is witnessing a solid adoption while its pipeline programs are also progressing well. However, excessive reliance on Yupelri for revenues is a woe.

  • Thermo Fisher Closes API Site Buyout, Fortifies Pharma Unit
    Zacks

    Thermo Fisher Closes API Site Buyout, Fortifies Pharma Unit

    Following the acquisition closure of GlaxoSmithKline's plant, Thermo Fisher (TMO) will continue to manufacture APIs for the same under a multi-year supply agreement.

  • The Zacks Analyst Blog Highlights: J&J, AstraZeneca, Roche, Glaxo and Merck
    Zacks

    The Zacks Analyst Blog Highlights: J&J, AstraZeneca, Roche, Glaxo and Merck

    The Zacks Analyst Blog Highlights: J&J, AstraZeneca, Roche, Glaxo and Merck

  • AstraZeneca's Fasenra Gets FDA Nod for Self-Administration
    Zacks

    AstraZeneca's Fasenra Gets FDA Nod for Self-Administration

    The FDA approval of the self-administration option and auto-injector of AstraZeneca's (AZN) Fasenra is supported by data from the phase III GRECO study and the phase I AMES study

  • Pharma Stock Roundup: JNJ's Opioid Settlement, FDA Updates for AZN, GSK, MRK, RHHBY
    Zacks

    Pharma Stock Roundup: JNJ's Opioid Settlement, FDA Updates for AZN, GSK, MRK, RHHBY

    J&J (JNJ) settles with two Ohio plaintiffs for $10 million. FDA updates for AstraZeneca (AZN), Merck (MRK) and others and ESMO presentations by big pharma companies in focus.

  • Gilead's Descovy HIV Regimen Gets FDA Nod for Label Expansion
    Zacks

    Gilead's Descovy HIV Regimen Gets FDA Nod for Label Expansion

    Gilead (GILD) obtains FDA approval for HIV treatment Descovy as a prevention option.

  • J&J Gets Breakthrough Therapy Tag for Prostate Cancer Drug
    Zacks

    J&J Gets Breakthrough Therapy Tag for Prostate Cancer Drug

    J&J (JNJ) announces that the FDA has granted Breakthrough Therapy status to its PARP inhibitor, niraparib, for the treatment for advanced prostate cancer.

  • What Kind Of Investor Owns Most Of GlaxoSmithKline plc (LON:GSK)?
    Simply Wall St.

    What Kind Of Investor Owns Most Of GlaxoSmithKline plc (LON:GSK)?

    A look at the shareholders of GlaxoSmithKline plc (LON:GSK) can tell us which group is most powerful. Large companies...

  • Drugmakers in spotlight as GSK recalls Zantac
    Reuters Videos

    Drugmakers in spotlight as GSK recalls Zantac

    Popular heartburn medicine Zantac may be rather less popular after a move by its makers to recall it. The decision, says GlaxoSmithKline, a 'precaution' ... After the U.S. FDA found "unacceptable" levels of probable cancer-causing impurity in the drug. It's not the first such move for what is also sold generically as ranitidine. Swiss drugmaker Novartis halted global distribution last month. Last week, Walmart and CVS Health, Walgreens Boots Alliance and Rite Aid suspended over-the-counter sales. Canada has asked drugmakers to halt distribution - Ireland and Hong Kong have pulled products. UK regulators said GSK was recalling four prescription-only Zantac medicines. An over-the-counter version made by a different company is not affected. Also in the sector spotlight: Johnson & Johnson. The drugs and consumer goods giant ordered to pay eight billion dollars in punitive damages ... To a plaintiff in the US, a Philadelphia jury has said. The damages dwarf an initial 680,000 dollar award ... Which concerns claims J&J failed to warn that young men using its antipsychotic drug Risperdal could grow breasts. Thousands of Risperdal cases are pending in the state.